Successful Treatment of Familial Mediterranean Fever with Infliximab in a Colchicine Resistant PatientVanesa Antón Vázquez1*, Elena Güell Farré1, David Brandariz Nuñez2, Hector and Corominas3
- *Corresponding Author:
- Vanesa Antón Vázquez
Servicio de Medicina Interna
Hospital Moisès Broggi, Barcelona, Spain
E-mail: [email protected]
Received date: February 13, 2017; Accepted date: March 22, 2017; Published date: March 27, 2017
Citation: Vázquez VA, Farré EG, Nuñez DB, Corominas H (2017) Successful Treatment of Familial Mediterranean Fever with Infliximab in a Colchicine Resistant Patient. J Clin Case Rep 7:938. doi: 10.4172/2165-7920.1000938
Copyright: © 2017 Vázquez VA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent episodes of fever and inflammation. Approximately 10% of patients are reported to be resistant or non-responsive to colchicine. We describe a case of a 30-year-old female patient with familial Mediterranean fever resistant to treatment with colchicine and lack of clinical response to Anakinra, successfully treated with Infliximab. Our case suggests that Infliximab, an anti-TNF antibody, may represent a safe and effective therapy for the treatment of colchicine-resistant FMF.